Mankind Q2 FY27: consolidated PAT +38% YoY to ₹716 Cr as margins clear guidance band
PAT +37.67% YoY · revenue +17.33% · margins expanding · beat vs street
₹4,337.86 Cr
+17.33% YoY
₹716.12 Cr
+37.67% YoY
16.16%
+2.4pp YoY
₹17.23
Mankind Pharma's consolidated Q2 FY27 (quarter ended September 30, 2026) print came in ahead of both the Street and the company's own guidance. Revenue from operations rose 17.3% YoY to ₹4,337.86 Cr (from ₹3,697.16 Cr) and 7.6% QoQ (from ₹4,030.59 Cr), above the ₹4,050–4,150 Cr range our pre-result preview flagged as the on-plan expectation. Consolidated profit for the period rose 37.7% YoY to ₹716.12 Cr (from ₹520.18 Cr) and 24.7% QoQ (from ₹574.09 Cr); the share attributable to equity holders of the parent was ₹711.48 Cr, taking basic EPS to ₹17.23 from ₹12.39 a year earlier. Both figures beat the preview's ~₹560–610 Cr PAT expectation. There were no exceptional items in either the current or year-ago quarter, so the growth is not a base-effect artifact.
Q2 FY-2027 vs prior quarters
Profit grew faster than revenue because margins expanded on every line. EBITDA margin (OPM) came in at ~27.1% of revenue from operations, up from 24.9% YoY and 26.2% QoQ, and above the top end of management's reaffirmed 25.5–26.5% FY27 guidance band. Gross margin held at ~72.2%, above the >71% floor the company had guided to even while flagging a West Asia headwind on the last call. Net profit margin followed through to 16.5%, up from 13.7% YoY and 14.1% QoQ — though the effective tax rate rose to ~22.9% of PBT from ~16.6% a year ago, so pre-tax profit (₹929.11 Cr, +48.9% YoY) outpaced the 37.7% PAT growth due to that higher tax incidence.
The stock went into the print at ₹2,312, down 6.2% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 3 consecutive quarters; revenue is at a 6-quarter high.
FY27 double-digit revenue growth maintained. EBITDA margin guidance 25.5–26.5% reaffirmed. Capex 6–7% of revenue (Q1 at 4.9%). Gross margin >71% with West Asia headwind. Consumer Healthcare: high single-digit to double-digit growth from Q2 onwards.
— This quarter: beat
Against prior guidance, this is a clear beat rather than a mere confirmation: management had reaffirmed double-digit FY27 revenue growth and the 25.5–26.5% margin band on the August concall, and the print cleared both. The Street's pre-result consensus (19 analysts, Buy-biased, ₹2,712–2,718 target) was built on FY27 revenue of ₹160.2b and EPS of ₹56.90; this quarter's run-rate is consistent with that path rather than requiring a cut. Corporate activity this quarter was mostly structural: the Board approved two intra-group amalgamation schemes on results day (Prolijune Lifesciences and Pavi Buildwell into Mankind Pharma; Upakarma Ayurveda into Mankind Consumer Products) to simplify the group structure, alongside the already-flagged ACTx (CAR-T/oncology) stake acquisition via an incremental EUR 45–50Mn investment in the Netherlands subsidiary — consistent with management's own framing (via our pre-result preview) that ACTx is a long-term portfolio pivot and explicitly not Q2-accretive; the quarter's numbers show no visible CAR-T-related drag or lift. BSV's subsidiary liquidation/auditor resignation and the completed Broadway Hospitality divestment were housekeeping items with no visible P&L impact. No standalone management press release accompanied this filing to independently cross-check against.
W1
FY27 margin trajectory vs the 25.5–26.5% EBITDA band — Q2 OPM at ~27.1% is already running above the top end
W2
Consumer Healthcare growth (management guided high-single to double-digit from Q2) is not independently verifiable this quarter — the Group reports only one segment ('Pharmaceuticals') under Ind AS 108
W3
ACTx (CAR-T) integration and the EUR 45–50Mn Netherlands investment — flagged as long-term and non-accretive near-term; watch for Q3 cost impact
Digitally typeset, fully legible filing — both standalone and consolidated statements clearly column-labelled. Consolidated PAT 716.12 Cr is 'profit for the period' before NCI split (matches our DB convention/prior-quarter comparables); PAT attributable to equity holders of the parent is 711.48 Cr and is the basis for the 17.23 basic EPS. No exceptional items in the current quarter on either standalone or consolidated basis, nor in the year-ago quarter — unlike FY26 full-year figures which carried exceptional charges (106.24 Cr standalone / 129.75 Cr consolidated), so no adjusted-vs-raw growth split is needed this quarter.
Margin beat masks consumer healthcare turnaround pending
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Q2 met revenue/EBITDA margin guidance, beat Capex guidance, but Consumer Healthcare guidance missed by acknowledged weak category offtake.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Q2 beat on EBITDA margins (27.1% vs 25.5–26.5% guidance) and delivered 17.3% revenue growth on-plan. However, Consumer Healthcare explicitly underperformed guidance, and management conceded being 'unhappy' with this segment. Margin upside is offset by CH recovery risk in FY28 and a tax rate jump to 24% (from 17.1%), creating near-term headwind.
₹4338 Cr
Revenue · +17.3% YoY₹716 Cr
Reported PAT · +37.7% YoYExpanding
Margins · vs guidance: MixedDid the claims hold up?
Revenue up 17% YoY to ₹4,338 Cr
METDelivered ₹4,337.9 Cr, +17.3% YoY — exactly matched
EBITDA margin 27.1%, beat guidance of 25.5–26.5%
METDelivered 27.1%, +210 bps YoY — beat upper end by 60 bps
Consumer Healthcare high single-digit to double-digit growth from Q2
MISSCH delivered ₹229 Cr, slower growth due to category headwind — missed
PAT grew 37.7% YoY to ₹716 Cr
METDelivered ₹716.1 Cr, +37.7% YoY — exactly matched
International revenue up 33% to ₹680 Cr
METReported ₹680 Cr, +33% YoY — on track for double growth target
Gross margin >71% guidance achieved at 72.2%
METDelivered 72.2%, +90 bps YoY, beat 71% floor
Earnings quality
What changed since the last call
EBITDA margin exceeded guidance
UpgradePrior guidance 25.5–26.5%, Q2 achieved 27.1%. Driven by gross margin expansion 72.2% and operating leverage.
Consumer Healthcare flagged as weak
DowngradeGuidance promised high single-digit to double-digit from Q2. Delivered slower growth due to category headwind. Management explicitly 'unhappy'.
Tax rate regime change impact
DowngradeEffective tax rate rose to 24% from 17.1% due to tax exemption expiry, compressing PAT by 690 bps, unguided headwind.
International business tracking double-digit
NeutralQ2 +33% YoY, tracking towards FY27 double-growth target. BSV specialty brands +34%, Mankind International +29%.
The Q&A
Analysts pressed hard on Consumer Healthcare weakness and margin sustainability. Management held ground on core strategy but conceded CH underperformance. On GLP-1 and chronic ceiling, management gave limited color, deflecting to 4–5-year ambition. Tax impact was disclosed, not pre-flagged—credibility cost.
Export growth drivers — Rashmi Shetty, Dolat Capital
AnsweredGuidance 20% growth; actual 30% driven by BSV (+34%), Mankind International (+29%). Currency benefit supports upward delta vs guidance.
EBITDA margin ceiling — Rashmi Shetty, Dolat Capital
Partial27% is high-end guidance run. Operating leverage will support future expansion, but management cautious on quantifying peak level.
Domestic IPM underperformance — Neha Manpuria, Bank of America
PartialYes, legacy shows 1.3–1.4x IPM beat. Management confident correction will resume, but conceded recent quarters were weak.
Margin mix compression risk — Neha Manpuria, Bank of America
AnsweredR&D guidance 2.8% to 3% of revenue, FY27 upper end. ACTx is early-stage, funding €48M committed through FY28, no material dilution yet.
Consumer Healthcare turnaround — Rashmi Shetty, Dolat Capital
DodgedManagement unhappy with CH performance. E-commerce growing 100%, but overall segment weak. Recovery expected FY28, no firm timeline.
Brand portfolio expansion — Bansi Desai, JP Morgan
AnsweredUpward 20–25% growth in mandate brands over 4 quarters. Chronic specialty brands (Anti-D, Foligraf) showing 30–40% growth. Momentum sustained.
Chronic share ceiling ambition — Niharika Agarwal, Nirmal Bang
PartialQ2 base always higher, chronic margin ~37%. Goal is 100–200 bps annual expansion. Realistic ceiling 50% given market dynamics.
GLP-1 strategy in consumer health — Alankar Garude, Kotak Institutional Equities
DodgedOTC CAGR lagging. New brand strategy: shift successful OTC products to prescription (Gas-O-Fast), then back to consumer. Limited GLP-1 color given.
Hospital segment expansion — Umesh Laddha, institutional investor
AnsweredHospital growth broad-based, but earlier over-indexed to Tier-2 to Tier-6. Now shifting to Tier-1 and metros. Long-term growth potential sustainable.
Margin regulatory risk — Simran Thakkar, Beas Capital
AnsweredUCPMP guideline voluntary so far, been preparing 3–4 years. Confident of compliance with government's future statutory rules; no material margin impact expected.
Guidance
FY27 double-digit revenue growth reaffirmed
HighH1 FY27 +17.3% YoY on base effects. Full-year assumes growth above 12–13% IPM rate. Consumer HC turnaround needed for beat.
EBITDA margin 25.5–26.5% for FY27, achieved 27.1% in Q2
HighQ2 beat 60 bps above upper end. Driven by gross margin expansion and operating leverage. Sustainability depends on chronic share growth offsetting CH mix headwind.
Gross margin >71%, achieved 72.2% in Q2
HighPrice increases and chronic mix expansion offset West Asia headwind. Outlook stable subject to FX and input cost dynamics.
Capex 6–7% of revenue for FY27, running 4.9% in H1
HighH1 FY27 ₹214 Cr capex. Full-year tracking below guidance. Capacity expansion for chronic and specialty therapies underway.
Risks the call surfaced
Consumer Healthcare turnaround
MediumConsumer Healthcare delivered ₹229 Cr with slower growth vs prior guidance of 'high single-digit to double-digit from Q2'. Management acknowledged being 'unhappy'. E-commerce growing 100%, but base offtake weak.
Tax rate increase
MediumEffective tax rate jumped from 17.1% to 24% in H1 FY27 due to expiry of corporate tax exemption. Impact ~₹180+ Cr on full-year PAT, unguided headwind.
Chronic therapy margin compression
LowChronic therapies expanding to 50% of domestic portfolio (from current 37%) over 4–5 years. Chronic margin (~37%) below acute specialty (BSV ~28% margin), so mix shift could compress overall EBITDA margin.
IPM underperformance
LowIndia pharma market (IPM) growing 12–13% per annum. Mankind targeting 11–12% CAGR in India domestic, slightly below market. Acute therapies growth lags, suggesting pricing or volume compression in competitive segments.
Regulatory / marketing compliance
LowUCPMP (Uniform Code of Pharmaceutical Marketing Practices) marketing guideline Supreme Court hearing Jan 29, 2027. Outcome could restrict promotional spend or impose stricter compliance, impacting sales execution.
Management
Score 6/10. Clear on financial metrics and segment performance. Transparent on Consumer Healthcare weakness ('unhappy'). Limited color on GLP-1 strategy, ACTx funding mechanics, and margin ceiling quantification. Good at defending against tough Q&A. Met Q2 revenue and EBITDA margin guidance. PAT beat on back of margin upside. Capex tracking below guidance. Consumer Healthcare turnaround delayed vs prior promise. Tax headwind unguided but now disclosed.
1 · Q3 FY27
Consumer Healthcare recovery expected, seasonal strength in acute
2 · Jan 2027
UCPMP marketing guidelines Supreme Court hearing
3 · FY28
ACTx CAR-T clinical trials progress (€48M funding commitment)
Margin upside is offset by CH recovery risk in FY28 and a tax rate jump to 24% (from 17.1%), creating near-term headwind.
Margin Beat Masks Consumer Healthcare Turnaround Risk
Mankind beat EBITDA margin guidance at 27.1% and grew PAT 37.7% YoY, but Consumer Healthcare explicitly missed guidance and management is unhappy. A 690 bps tax rate jump adds to the near-term headwind—the question is whether margin upside can sustain if the turnaround stalls.
+17.3%
Q2 FY27 ₹4,338 Cr
27.1%
Beat 25.5–26.5% guidance by 60 bps
+37.7%
Margin expansion offset tax headwind
24%
Up 690 bps from 17.1%, ₹180+ Cr annual drag
On paper, Mankind's Q2 looks like a strong quarter: 17.3% revenue growth, EBITDA margin beat, PAT up 37.7%. But the headline obscures the real story. Consumer Healthcare explicitly missed guidance ('slower growth' vs 'high single-digit to double-digit from Q2'), management admitted being 'unhappy' with the segment, and a 690 bps jump in the effective tax rate to 24% is an unguided headwind. The margin beat is real and well-earned—but it's masking near-term execution risk.
Where the growth came from
Revenue grew 17.3% YoY to ₹4,338 Cr, on track with FY27 double-digit guidance. The growth is broad-based: domestic excl. Consumer Healthcare +15.9%, international +33%, and hospital segment +23%. But Consumer Healthcare, which was promised to recover to 'high single-digit to double-digit growth from Q2,' delivered slower growth. Management conceded the segment is facing category headwind (OTC offtake weak) and regional weakness (East and South underperforming). E-commerce is surging 100%, but it's not enough to offset the base business softness.
The real earnings driver, however, was margin expansion. EBITDA margin reached 27.1%, beating the 25.5–26.5% guidance by 60 basis points and expanding 210 bps YoY. Gross margin expanded 90 bps to 72.2% (above the >71% floor) on price increases, chronic mix favorability, and operating leverage offsetting West Asia headwind. This margin beat more than offset a 690 bps jump in the effective tax rate (from 17.1% to 24%) due to the expiry of the corporate tax exemption period, driving PAT growth of 37.7% despite the tax headwind.
What management claimed vs. what holds up
Revenue +17% YoY, FY27 double-digit growth maintained
Delivered ₹4,338 Cr, +17.3% YoY
Supported ✓
EBITDA margin 25.5–26.5% FY27 guidance
Q2 achieved 27.1%, beat upper end by 60 bps
Supported & beaten ✓
Gross margin >71%
Delivered 72.2%, +90 bps YoY
Supported ✓
Consumer Healthcare high single-digit to double-digit growth from Q2
CH delivered ₹229 Cr with slower growth; e-comm +100% but base weak
Contradicted ✗
International +33%, tracking FY27 double-growth target
Reported ₹680 Cr, +33% YoY (BSV +34%, Mankind Intl +29%)
Supported ✓
Capex 6–7% of revenue
H1 running 4.9% (₹214 Cr), below guidance
Tracking below ✓
I should really confess you that we are unhappy with our own performance in consumer business.
What changed on this call
EBITDA margin exceeded guidance — 27.1% vs 25.5–26.5%, a 60 bps upside. Driven by gross margin expansion (72.2%, +90 bps) and operating leverage. This is genuine execution.
Consumer Healthcare explicitly flagged as weak — Guidance promised 'high single-digit to double-digit growth from Q2'; delivered slower growth. Management conceded category headwind (OTC weakness) and regional softness (East, South). Recovery pushed to FY28, no firm timeline.
Tax rate regime change — Effective tax rate jumped 690 bps to 24% from 17.1% due to corporate tax exemption expiry. Unguided headwind of ₹180+ Cr annually on PAT. Permanent structural change, not one-time.
Working capital deterioration — WC days increased to 51 from 46 prior year on higher inventory. Cash-to-EBITDA ratio dropped to 81% from 92%. Minor but signals cash flow drag.
International tracking ahead — +33% YoY vs double-growth FY27 target. BSV specialty brands +34%, Mankind International +29%. On track.
The bull-bear ledger
Revenue growth 17.3% YoY—above IPM (12–13%), on track for FY27 double-digit guidance
EBITDA margin beat: 27.1% vs 25.5–26.5% guidance, +210 bps YoY. Genuine operating leverage.
Chronic therapies expansion: now 37% of domestic, targeting 50% in 4–5 years. Structural growth driver.
9 new brand families >₹50 Cr added; 4 brands now >₹100 Cr (26 total vs 22). Portfolio momentum sustained.
International +33%, on pace for double growth target. BSV specialty (+34%) and emerging markets (ASEAN, Africa, MENA) expanding.
Capex ₹214 Cr (4.9% of revenue), tracking below 6–7% guidance. Disciplined capital allocation.
Consumer Healthcare turnaround delayed—slower growth vs 'high single-digit to double-digit' promised. Management unhappy. E-commerce +100% doesn't offset base weakness.
Tax rate jumped 690 bps to 24% (from 17.1%). Unguided structural headwind of ₹180+ Cr annually on PAT growth.
Chronic share expansion (37% → 50% target) risks margin dilution—chronic margin ~37% vs acute specialty ~28%. Mix shift could compress EBITDA unless gross margin gains accelerate.
Working capital deterioration—WC days up to 51 from 46. Cash-to-EBITDA down to 81% from 92%. Mild but cash flow drag.
IPM underperformance in acute—domestic excl. CH growing 15.9% YoY, but acute categories (OTC, some acute Rx) lagging market. Suggests pricing or volume headwind.
UCPMP marketing compliance ruling (Jan 29, 2027) still pending. Could restrict promotional spend or impose stricter compliance if statutory rules stricter than voluntary guidelines.
Ranked risks—what should concern a holder
1. Consumer Healthcare turnaround execution
MediumIf CH recovery falters beyond FY28, revenue growth will miss the FY27 double-digit target and gross margin compression will offset EBITDA upside. Management's 'unhappy' concession suggests bigger problem than category headwind. Watch Q3–Q4 performance.
2. Tax rate permanent headwind
MediumThe 24% rate (up from 17.1%) is not temporary—it's due to exemption expiry. Cuts ₹180+ Cr annually from PAT, compressing normalized PAT growth to ~12–15% ex-margin expansion. FY27 and beyond PAT guidance needs to reflect this.
3. Chronic margin compression risk
LowChronic share target is 50% vs current 37%, expanding at ~80 bps annually. If chronic margin (~37%) stays below acute specialty (~28%), mix shift alone erodes 100–200 bps annually. Offset requires sustained gross margin gains. Realistic but execution-dependent.
4. IPM underperformance in acute
LowDomestic excl. CH growing 15.9% YoY vs IPM 12–13%, a 2–4% beat. But acute-specific categories (OTC especially) lagging. Suggests pricing or volume headwind in competitive segments.
5. Regulatory—UCPMP marketing framework (Jan 29, 2027)
LowSupreme Court ruling on UCPMP guideline could impose stricter statutory rules. Company has voluntarily prepared 3–4 years, confident of compliance, no material margin impact expected. But outcome is not guaranteed.
How the street is positioned
Price action & valuation: Mankind is trading at ₹2,469.3, above all key moving averages (SMA20 ₹2,389.86, SMA50 ₹2,380.27, SMA200 ₹2,311.95). The stock is up 29.3% off its 52-week low (₹1,909.7) but down 19.17% from its all-time high (₹3,054.8), placing it in a neutral-to-strong mid-cycle position. RSI at 56.9 is neutral, suggesting room to run in either direction. Volume is increasing, signaling institutional interest.
Ownership flows: FII shareholding fell 79 basis points QoQ to 9.45% (from 10.24% in Q1), a material pullback for a flagship pharma name. Conversely, DII ownership rose 93 basis points to 15.39% (from 14.46%), suggesting domestic institutions are stepping in as foreigners trim. Promoter stake is stable at 72.63%. The FII outflow is notable—it suggests the market is cautious on the Consumer Healthcare story and the tax headwind, despite the margin beat. DII's inflow signals domestic funds see value, but the FII move is a warning flag that near-term headwinds are real.
Market's verdict on the beat: The margin beat (27.1% vs 25.5–26.5%) is being priced in as expected—not enough to attract incremental FII at current levels. The Consumer Healthcare miss and tax headwind are outweighing the positives. The stock's 19% drawdown from ATH and neutral RSI suggest the market is in 'prove it' mode: management needs to deliver on Consumer Healthcare recovery by Q4 FY27 to re-attract foreign capital. Until then, the FII outflow is likely to continue.
The debate
The honest read: Mankind delivered genuine operating leverage in Q2—margin beat is real and well-earned. But the underlying business story is mixed: core domestic and international are solid, but Consumer Healthcare is broken and management has no clear timeline to fix it. The 37.7% PAT growth is inflated by margin expansion offsetting a tax headwind; the organic earnings growth is closer to 12–15%. The real debate is not whether Q2 was strong (it was), but whether Mankind can sustain 27% EBITDA margins while simultaneously resurrecting Consumer Healthcare without margin compression. That's a high bar—and the FII pullback suggests the street thinks Mankind will miss it.
What to watch next
1 · Consumer Healthcare recovery in Q3–Q4 FY27
This is the make-or-break catalyst. Management expects recovery to start in Q3 (seasonal strength in acute, new brand portfolio, e-commerce momentum). If CH shows positive momentum (high single-digit to double-digit growth) in Q3, it validates the turnaround thesis. If growth stays flat or negative, the FY28 growth story breaks and margin compression risk becomes real. Watch: Q3 CH revenue, e-commerce penetration, and management commentary on category trends.
2 · FY28 EBITDA margin guidance
Management has guided 25.5–26.5% for FY27, and Q2 beat at 27.1%. The question is whether 27% was a peak or a sustainable run-rate. If FY28 guidance is 26.5–27%, it signals management believes the margin is durable (bullish). If guidance drops to 25–26%, it signals concession to Consumer Healthcare mix headwind or chronic share pressure (bearish). This will be revealed at Q4 results or strategy day.
3 · Chronic share progression and gross margin trends
Chronic is now 37%, targeting 50% in 4–5 years. The question is whether gross margin expansion can offset the dilution from mix shift. Watch: Q3–Q4 chronic revenue growth rate, gross margin trend, and BSV specialty momentum (which carries higher margins). If chronic grows faster than BSV, mix compression risk rises.
4 · Jan 29, 2027 UCPMP Supreme Court ruling
The outcome will determine whether the voluntary compliance preparation pays off or new constraints emerge. If the ruling imposes stricter rules, promotional spend could be restricted, affecting sales force reach. Watch for management guidance on potential impact post-ruling.
The single number to track from here
Organic PAT growth excluding tax headwind. The reported 37.7% PAT growth is inflated by margin expansion (which is real) offsetting the 690 bps tax rate jump (which is permanent). Backing out the margin contribution and tax headwind, the organic PAT growth is closer to 12–15%, in line with revenue growth. That's the sustainable number. If FY28 guidance drops the margin guidance and the tax headwind persists, organic PAT growth will decelerate to 10–12%. That's when Mankind will need Consumer Healthcare to deliver, or the stock will face pressure. Track: the management's explicit guidance on FY27 and FY28 normalized PAT growth ex-tax impact.
Mankind's Q2 was a good quarter masked as a great one. The margin beat is genuine and the revenue growth is on-plan, but Consumer Healthcare is a real problem and the tax headwind is permanent. The stock is fairly valued at 15–16x FY27 earnings, but it's priced for a Consumer Healthcare recovery that management hasn't yet demonstrated. The FII outflow is the street's way of saying: 'Prove the turnaround before we own it again.' Until Mankind delivers on that promise—likely Q4 FY27 or Q1 FY28—the stock is a Hold for existing holders and a cautious Buy on weakness to new money. The real test is not Q2's margin beat; it's whether Mankind can sustain 27% EBITDA margins while fixing Consumer Healthcare. That's the single debate that matters.
Margins hold the line as Mankind navigates acquisition & consolidation
Q2 revenue expected to track guidance (est. ₹4,050–4,150 Cr, +10–13% YoY) with EBITDA margin staying within the 25.5–26.5% band. The Street waits for margin consistency post-ACTx acquisition and BSV integration—and clarity on FY27 full-year run-rate after FII outflows pressured the stock 26% from peak.
What to expect
~₹4,050–4,150 Cr
Q1 was ₹4,031 Cr (+12.9% YoY); FY27 guidance is 10% growth. Expect sequential flatness or modest 1–2% growth; domestic steady, exports to remain a driver.
25.5–26.5%
Guidance band maintained. Q1 landed 26.3%; management target is mid-range consistency despite raw material & geopolitical headwinds. Watch for any BSV integration cost drag.
~₹560–610 Cr
Q1 PAT was ₹574 Cr, margin 14.2%. Expect mid-14% range; finance costs (ACTx debt & acquisition spend) could pressure margin ~30–50 bps.
>71%
Guidance is above 71%. Q1 implied ~71.8% (EBITDA + D&A + OpEx). Sustainable given BSV mix & cost management, but inflation/FX a headwind.
A strong Q2 holds margin at >26% and guides FY27 full-year at 25.5%+, with exports accelerating (10%+ growth). Weak: margin compresses below 25.5% or domestic revenue flat/negative YoY, signaling price pressure or volume loss in core markets. Street consensus is for margin discipline; any slip on operating leverage or gross margin will rattle positioning.
On track?
Yes, so far. Q1 FY27 confirmed the guidance: 12.9% revenue growth above the 10% full-year target, EBITDA margin at 26.3% (upper half of 25.5–26.5% band), and PAT margin expanded 170 bps YoY. The slope is right. Q2 will be watched as a mid-year anchor—if margins stay above 25.5% and domestic revenue momentum is steady (even if growth slows to 8–10%), the company tracks the half-year plan. The real test: whether ACTx acquisition (announced Oct 15, post-quarter close) and BSV integration (Sept 2026 liquidation effective) signal strategic repositioning or financial drag. Management has guided Q2 results will reflect integration benefits, not costs.
What the Street says
Since last quarter
1 · ACTx acquisition (Oct 15) – strategic, not accretive to Q2
Mankind approved acquisition of 70% stake in Armed Cell Therapeutics B.V. (Belgium CAR-T specialist) for EUR 50Mn (plus contingent consideration). Wholly-owned subsidiary Mankind Pharma (Netherlands) B.V. is the acquirer. No Q2 impact; expected to move profitability forward post-integration (FY28–29 horizon per Street view). Board noted ESG improvement (NSE rating 71), so governance narrative intact.
2 · BSV liquidation & consolidation (Aug–Sep) – operational tidying
Bharat Serums & Vaccines BSVL approved voluntary liquidation & integration into parent (Aug 26, 2026). Auditors resigned Sep 28 (routine for liquidation). Business consolidated into parent; export upside (~29% growth in Q1 on BSV contribution) expected to continue. No profit/loss restatement flagged; integration treatment TBD in Q2 P&L notes.
3 · Broadway Hospitality divestment (Aug 31) – exit complete
100% stake in Broadway Hospitality Services (subsidiary) sold to AKRK Projects & Partners. Non-core, immaterial. Routine for portfolio streamlining; no ongoing drag.
4 · ESG & governance upgrades – narrative tailwind
ESG rating improved to 71 (NSE, Oct 15) and 68.21 (Niche99, Sep 15, 'Leader' rank). Independent director Anish Vanraj Bafna appointed (Aug 10). Reinforces governance quality; likely to appeal to returning FII.
5 · FII outflows & trading window closure – valuation pressure
FII ownership down to 9.45% from 13.07% YoY (370 bps outflow). Trading window closed Sep 25 – Oct 1 (pre-result); reflects pre-announcement profit-taking. Stock down 26% from ATH; P/E compression from 19x → 16x reflects pause in momentum narrative.
6 · Debt & security realignment (Aug 17) – housekeeping
Security cover for NCDs realigned post-BSV pledge release; no covenant breach or concern flagged. Routine post-divestment adjustment.
The setup
Mankind reports Q2 FY27 on Oct 26 as a margin-defense story: can the 26.3% EBITDA margin from Q1 hold (or exceed) despite BSV integration and ACTx investment? Revenue at ₹4,050–4,150 Cr would confirm the 10% FY27 guidance is on track; exports remain the wildcard, and domestic steady-state matters for confidence in H2. The Street has repriced off peak (buy-signal basis), but FII exit is a caution flag—execution clarity on Q2 and FY27 margins will determine whether the pin holds or breaks. Watch for: (1) margin band, (2) gross margin resilience, (3) domestic growth pace, (4) export carry-forward, (5) management commentary on ACTx integration timeline & near-term capital allocation.
Mankind Pharma Q2 FY27 is a mid-year checkpoint on guidance fidelity. The stock is down 26% from peak on valuation compression and FII profit-taking, not earnings miss. Street remains constructive (target ₹2,712+) if margins hold the 25.5–26.5% band and revenue growth stays in single-digit-to-mid-teen range. Q2's P&L will either validate H2 momentum or signal a reset—margin beat would be accretive; margin miss (below 25.5%) or weak domestic growth would invite further downgrades. ACTx is a long-term optionality play; near-term focus is operational leverage in the core pharma business.